|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
14.860 -0.160 (-1.065%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 17,034,255 | 11.564% | 15,268,660 | 10,290,050 | 5,612,384 | 3,983,687 |
| Cost of Sales | (10,206,354) | 19.447% | (8,544,646) | (5,461,153) | (3,079,418) | (2,324,858) |
| Gross Profit | 6,827,901 | 1.545% | 6,724,014 | 4,828,897 | 2,532,966 | 1,658,829 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (319,970) | 23.768% | (258,525) | (156,667) | (121,062) | (6,842) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 2,632 | (3,119) | |
| Profit / (Loss) before Taxation | 4,173,803 | -22.098% | 5,357,771 | 3,993,119 | 1,965,760 | 1,126,633 | |
| Taxation | (603,179) | -25.337% | (807,865) | (484,538) | (273,066) | (116,296) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (170,895) | 31.843% | (129,620) | (120,103) | (3,808) | 3,468 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,399,729 | -23.088% | 4,420,286 | 3,388,478 | 1,688,886 | 1,013,805 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (60,690) | 40.835% | (43,093) | (18,835) | (38,132) | (44,251) |
| Depreciation & Amortisation | 1,385,662 | 32.855% | 1,042,990 | 703,098 | 459,037 | 335,951 |
| Directors' Emoluments | 132,940 | 25.624% | 105,824 | 66,590 | 40,065 | 32,177 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 82.000 | -22.642% | 106.000 | 81.000 | 43.000 | 27.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 1.121 | -- | 1.328 | 0.822 | 0.476 | 0.325 |
| NBV per share ($) | 9.473 | -- | 8.295 | 7.579 | 5.034 | 3.292 |
| Remarks: | Real time quote last updated: 18/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,499,080 |
| %Change | -33.864% |
| EPS / (LPS) | RMB 0.370 |
| NBV Per Share (¥) | RMB 9.789 |